Clinical Trial Update: Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD) [Phase 3]

View source ↗

Summary

Open-label Phase 3 safety study of an enteric-coated spheroid suspension in infants under 12 months with presumed gastroesophageal reflux disease. The study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Enteric-Coated Spheroid Suspension

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Gastroesophageal Reflux | Phase 3 | Status: COMPLETED | Results posted: 2010-01-07